CN111956791A - Degradable slow-release invisible eye mask capable of eliminating asthenopia and preparation method thereof - Google Patents
Degradable slow-release invisible eye mask capable of eliminating asthenopia and preparation method thereof Download PDFInfo
- Publication number
- CN111956791A CN111956791A CN202010903316.7A CN202010903316A CN111956791A CN 111956791 A CN111956791 A CN 111956791A CN 202010903316 A CN202010903316 A CN 202010903316A CN 111956791 A CN111956791 A CN 111956791A
- Authority
- CN
- China
- Prior art keywords
- eye mask
- release
- invisible eye
- vitamin
- invisible
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 54
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 claims abstract description 54
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 36
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims abstract description 36
- 229930003270 Vitamin B Natural products 0.000 claims abstract description 30
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 30
- 239000011720 vitamin B Substances 0.000 claims abstract description 30
- 229960000686 benzalkonium chloride Drugs 0.000 claims abstract description 27
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960004926 chlorobutanol Drugs 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 27
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 20
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 20
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 20
- 102000008186 Collagen Human genes 0.000 claims abstract description 19
- 108010035532 Collagen Proteins 0.000 claims abstract description 19
- DJDFFEBSKJCGHC-UHFFFAOYSA-N Naphazoline Chemical compound Cl.C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 DJDFFEBSKJCGHC-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229920001436 collagen Polymers 0.000 claims abstract description 19
- 229960004760 naphazoline hydrochloride Drugs 0.000 claims abstract description 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 18
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 18
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 18
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 claims abstract description 18
- DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims abstract description 18
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims abstract description 18
- 235000004866 D-panthenol Nutrition 0.000 claims abstract description 18
- 239000011703 D-panthenol Substances 0.000 claims abstract description 18
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 18
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims abstract description 18
- 235000006679 Mentha X verticillata Nutrition 0.000 claims abstract description 18
- 235000002899 Mentha suaveolens Nutrition 0.000 claims abstract description 18
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims abstract description 18
- 229960002684 aminocaproic acid Drugs 0.000 claims abstract description 18
- 229940116229 borneol Drugs 0.000 claims abstract description 18
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229960003949 dexpanthenol Drugs 0.000 claims abstract description 18
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940041616 menthol Drugs 0.000 claims abstract description 18
- 229950008882 polysorbate Drugs 0.000 claims abstract description 18
- 229920000136 polysorbate Polymers 0.000 claims abstract description 18
- 239000011780 sodium chloride Substances 0.000 claims abstract description 18
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims abstract description 15
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims abstract description 15
- 229940124274 edetate disodium Drugs 0.000 claims abstract description 15
- OSZNNLWOYWAHSS-UHFFFAOYSA-M neostigmine methyl sulfate Chemical compound COS([O-])(=O)=O.CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 OSZNNLWOYWAHSS-UHFFFAOYSA-M 0.000 claims abstract description 12
- 229960002253 neostigmine methylsulfate Drugs 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 16
- 229940046978 chlorpheniramine maleate Drugs 0.000 claims description 15
- 238000001035 drying Methods 0.000 claims description 14
- 230000008014 freezing Effects 0.000 claims description 14
- 238000007710 freezing Methods 0.000 claims description 14
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- 229960002362 neostigmine Drugs 0.000 claims description 6
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 description 57
- 238000012360 testing method Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 3
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 210000001747 pupil Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005299 abrasion Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a degradable slow-release invisible eye mask capable of eliminating asthenopia and a preparation method thereof, relating to the technical field of invisible eye masks, and the raw material components of the invisible eye mask, calculated by 10ml, comprise: 200-300 mg of collagen peptide, 0.8-1.2mg of hyaluronic acid, 64-6 mg of vitamin B, 121.8-2.2 mg of vitamin B, 9-11mg of dipotassium glycyrrhizinate, 0.18-0.22mg of naphazoline hydrochloride, 0.28-0.32mg of neostigmine methylsulfate, 0.8-1.2mg of chlorphenamine maleate, 80-150mg of glycerol, 7-9mg of dexpanthenol, 4-6mg of menthol, 805-7 mg of polysorbate, 5-7mg of borneol, 3-5mg of edetate disodium, 2-4mg of mint, 2-4mg of aminocaproic acid, 1-3mg of ethanol, 9-11mg of sodium chloride, 2-4mg of benzalkonium chloride solution and 3-5mg of chlorobutanol solution; the mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
Description
Technical Field
The invention relates to the technical field of invisible eye masks, in particular to a degradable slow-release invisible eye mask capable of eliminating eyestrain and a preparation method thereof.
Background
The contact lenses bring convenience to consumers, but frequent wearing of the contact lenses can cause dry eyes, and the consumers can not clean the contact lenses in time or pay attention to eye hygiene, can cause severe abrasion to the cornea of the eyes and even can influence the vision.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a degradable slow-release invisible eye mask for eliminating asthenopia and a preparation method thereof.
The raw material components of the invisible eye mask, calculated by 10ml, comprise: 200-300 mg of collagen peptide, 0.8-1.2mg of hyaluronic acid, 64-6 mg of vitamin B, 121.8-2.2 mg of vitamin B, 9-11mg of dipotassium glycyrrhizinate, 0.18-0.22mg of naphazoline hydrochloride, 0.28-0.32mg of neostigmine methylsulfate, 0.8-1.2mg of chlorphenamine maleate, 80-150mg of glycerol, 7-9mg of dexpanthenol, 4-6mg of menthol, 805-7 mg of polysorbate, 5-7mg of borneol, 3-5mg of edetate disodium, 2-4mg of mint, 2-4mg of aminocaproic acid, 1-3mg of ethanol, 9-11mg of sodium chloride, 2-4mg of benzalkonium chloride solution and 3-5mg of chlorobutanol solution; the mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
Preferably, the raw material components of the invisible eye mask, calculated by 10ml, comprise: 200mg of collagen peptide, 0.8mg of hyaluronic acid, 64 mg mg of vitamin B, 121.8mg of vitamin B, 9mg of dipotassium glycyrrhizinate, 0.18mg of naphazoline hydrochloride, 0.28mg of neostigmine mesylate, 0.8mg of chlorpheniramine maleate, 80mg of glycerol, 7mg of dexpanthenol, 4mg of menthol, 805 mg of polysorbate, 5mg of borneol, 3mg of edetate disodium, 2mg of mint, 2mg of aminocaproic acid, 1mg of ethanol, 9mg of sodium chloride, 2mg of benzalkonium chloride solution and 3mg of chlorobutanol solution.
Preferably, the raw material components of the invisible eye mask, calculated by 10ml, comprise: 225mg of collagen peptide, 0.9mg of hyaluronic acid, 0.64.5 mg of vitamin B, 121.9 mg of vitamin B, 9.5mg of dipotassium glycyrrhizinate, 0.19mg of naphazoline hydrochloride, 0.29mg of neostigmine methosulfate, 0.9mg of chlorpheniramine maleate, 97.5mg of glycerol, 7.5mg of dexpanthenol, 4.5mg of menthol, 805.5 mg of polysorbate, 5.5mg of borneol, 3.5mg of disodium edetate, 2.5mg of mint, 2.5mg of aminocaproic acid, 1.5mg of ethanol, 9.5mg of sodium chloride, 2.5mg of benzalkonium chloride solution and 3.5mg of chlorobutanol solution.
Preferably, the raw material components of the invisible eye mask, calculated by 10ml, comprise: 250mg of collagen peptide, 1mg of hyaluronic acid, 65 mg of vitamin B, 122 mg of vitamin B, 10mg of dipotassium glycyrrhizinate, 0.20mg of naphazoline hydrochloride, 0.3mg of neostigmine mesylate, 1mg of chlorpheniramine maleate, 115mg of glycerol, 8mg of dexpanthenol, 5mg of menthol, 806 mg of polysorbate, 6mg of borneol, 4mg of edetate disodium, 3mg of mint, 3mg of aminocaproic acid, 2mg of ethanol, 10mg of sodium chloride, 3mg of a benzalkonium chloride solution and 4mg of a chlorobutanol solution.
Preferably, the raw material components of the invisible eye mask, calculated by 10ml, comprise: 275mg of collagen peptide, 1.1mg of hyaluronic acid, 0.21mg of naphazoline hydrochloride, 0.31mg of neostigmine methosulfate, 1.1mg of chlorpheniramine maleate, 132.5mg of glycerol, 8.5mg of dexpanthenol, 5.5mg of menthol, 806.5 mg of polysorbate, 6.5mg of borneol, 4.5mg of edetate disodium, 3.5mg of mint, 3.5mg of aminocaproic acid, 2.5mg of ethanol, 10.5mg of sodium chloride, 3.5mg of benzalkonium chloride solution and 4.5mg of chlorobutanol solution.
Preferably, the raw material components of the invisible eye mask, calculated by 10ml, comprise: 300mg of collagen peptide, 1.2mg of hyaluronic acid, 66 mg mg of vitamin B, 122.2mg of vitamin B, 11mg of dipotassium glycyrrhizinate, 0.22mg of naphazoline hydrochloride, 0.32mg of neostigmine methosulfate, 1.2mg of chlorpheniramine maleate, 150mg of glycerol, 9mg of dexpanthenol, 6mg of menthol, 807 mg of polysorbate, 7mg of borneol, 5mg of edetate disodium, 4mg of mint, 4mg of aminocaproic acid, 3mg of ethanol, 11mg of sodium chloride, 4mg of benzalkonium chloride solution and 5mg of chlorobutanol solution.
The preparation method of the degradable slow-release invisible eye mask capable of eliminating asthenopia comprises the following steps: s1, uniformly mixing raw material components to prepare eye mask liquid; s2, dripping the eye mask liquid into a mold, freezing at a low temperature to solidify and form, demolding, and drying to obtain a dry degradable slow-release invisible eye mask capable of eliminating asthenopia; and S3, preparing the dried degradable slow-release invisible eye mask capable of eliminating asthenopia.
Preferably, in step S2, the low-temperature freezing is performed at-4 to 0 ℃ for 5 minutes.
Preferably, in step S2, the drying is performed at 20-45 deg.C for 10 minutes.
The invention has the beneficial effects that:
(1) the degradable slow-release invisible eye mask capable of eliminating asthenopia provided by the invention contains collagen peptide and hyaluronic acid, so that cornea damage can be prevented and repaired; vitamins and naphazoline hydrochloride are added in the raw material components, so that the eye fatigue can be effectively relieved, and common symptoms such as dry eyes and discomfort can be eliminated; the degradable slow-release invisible eye mask capable of eliminating asthenopia provided by the invention is gradually dissolved and releases effective components under the influence of human eyeball temperature after being worn, can effectively eliminate asthenopia, can be used for a long time, is bright and has high commercial value.
(2) The preparation method of the degradable sustained-release invisible eye mask for eliminating asthenopia provided by the invention is simple to operate, and can retain effective components to the maximum extent.
Detailed Description
Hereinafter, embodiments of the present invention will be described in detail. The following examples are only for illustrating the technical solutions of the present invention more clearly, and therefore are only examples, and the protection scope of the present invention is not limited thereby.
It is to be noted that, unless otherwise specified, technical or scientific terms used herein shall have the ordinary meaning as understood by those skilled in the art to which the invention pertains.
Example 1
A degradable slow-release invisible eye mask for eliminating asthenopia comprises the following raw material components in 10 ml: 200mg of collagen peptide, 0.8mg of hyaluronic acid, 64 mg mg of vitamin B, 121.8mg of vitamin B, 9mg of dipotassium glycyrrhizinate, 0.18mg of naphazoline hydrochloride, 0.28mg of neostigmine mesylate, 0.8mg of chlorpheniramine maleate, 80mg of glycerol, 7mg of dexpanthenol, 4mg of menthol, 805 mg of polysorbate, 5mg of borneol, 3mg of edetate disodium, 2mg of mint, 2mg of aminocaproic acid, 1mg of ethanol, 9mg of sodium chloride, 2mg of benzalkonium chloride solution and 3mg of chlorobutanol solution.
The mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
The preparation method of the degradable slow-release invisible eye mask capable of eliminating asthenopia comprises the following steps:
s1, uniformly mixing raw material components to prepare eye mask liquid;
s2, dripping the eye mask liquid into a mold, freezing at a low temperature to solidify and form, demolding, and drying to obtain a dry degradable slow-release invisible eye mask capable of eliminating asthenopia;
and S3, preparing the dried degradable slow-release invisible eye mask capable of eliminating asthenopia.
In step S2, the low-temperature freezing is performed at-4 to 0 ℃ for 5 minutes.
In step S2, the drying is carried out at 20-45 ℃ for 10 minutes.
Example 2
A degradable slow-release invisible eye mask for eliminating asthenopia comprises the following raw material components in 10 ml: 225mg of collagen peptide, 0.9mg of hyaluronic acid, 0.64.5 mg of vitamin B, 121.9 mg of vitamin B, 9.5mg of dipotassium glycyrrhizinate, 0.19mg of naphazoline hydrochloride, 0.29mg of neostigmine methosulfate, 0.9mg of chlorpheniramine maleate, 97.5mg of glycerol, 7.5mg of dexpanthenol, 4.5mg of menthol, 805.5 mg of polysorbate, 5.5mg of borneol, 3.5mg of disodium edetate, 2.5mg of mint, 2.5mg of aminocaproic acid, 1.5mg of ethanol, 9.5mg of sodium chloride, 2.5mg of benzalkonium chloride solution and 3.5mg of chlorobutanol solution.
The mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
The preparation method of the degradable slow-release invisible eye mask capable of eliminating asthenopia comprises the following steps:
s1, uniformly mixing raw material components to prepare eye mask liquid;
s2, dripping the eye mask liquid into a mold, freezing at a low temperature to solidify and form, demolding, and drying to obtain a dry degradable slow-release invisible eye mask capable of eliminating asthenopia;
and S3, preparing the dried degradable slow-release invisible eye mask capable of eliminating asthenopia.
In step S2, the low-temperature freezing is performed at-4 to 0 ℃ for 5 minutes.
In step S2, the drying is carried out at 20-45 ℃ for 10 minutes.
Example 3
A degradable slow-release invisible eye mask for eliminating asthenopia comprises the following raw material components in 10 ml: 250mg of collagen peptide, 1mg of hyaluronic acid, 65 mg of vitamin B, 122 mg of vitamin B, 10mg of dipotassium glycyrrhizinate, 0.20mg of naphazoline hydrochloride, 0.3mg of neostigmine mesylate, 1mg of chlorpheniramine maleate, 115mg of glycerol, 8mg of dexpanthenol, 5mg of menthol, 806 mg of polysorbate, 6mg of borneol, 4mg of edetate disodium, 3mg of mint, 3mg of aminocaproic acid, 2mg of ethanol, 10mg of sodium chloride, 3mg of a benzalkonium chloride solution and 4mg of a chlorobutanol solution.
The mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
The preparation method of the degradable slow-release invisible eye mask capable of eliminating asthenopia comprises the following steps:
s1, uniformly mixing raw material components to prepare eye mask liquid;
s2, dripping the eye mask liquid into a mold, freezing at a low temperature to solidify and form, demolding, and drying to obtain a dry degradable slow-release invisible eye mask capable of eliminating asthenopia;
and S3, preparing the dried degradable slow-release invisible eye mask capable of eliminating asthenopia.
In step S2, the low-temperature freezing is performed at-4 to 0 ℃ for 5 minutes.
In step S2, the drying is carried out at 20-45 ℃ for 10 minutes.
Example 4
A degradable slow-release invisible eye mask for eliminating asthenopia comprises the following raw material components in 10 ml: 275mg of collagen peptide, 1.1mg of hyaluronic acid, 0.21mg of naphazoline hydrochloride, 0.31mg of neostigmine methosulfate, 1.1mg of chlorpheniramine maleate, 132.5mg of glycerol, 8.5mg of dexpanthenol, 5.5mg of menthol, 806.5 mg of polysorbate, 6.5mg of borneol, 4.5mg of edetate disodium, 3.5mg of mint, 3.5mg of aminocaproic acid, 2.5mg of ethanol, 10.5mg of sodium chloride, 3.5mg of benzalkonium chloride solution and 4.5mg of chlorobutanol solution.
The mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
The preparation method of the degradable slow-release invisible eye mask capable of eliminating asthenopia comprises the following steps:
s1, uniformly mixing raw material components to prepare eye mask liquid;
s2, dripping the eye mask liquid into a mold, freezing at a low temperature to solidify and form, demolding, and drying to obtain a dry degradable slow-release invisible eye mask capable of eliminating asthenopia;
and S3, preparing the dried degradable slow-release invisible eye mask capable of eliminating asthenopia.
In step S2, the low-temperature freezing is performed at-4 to 0 ℃ for 5 minutes.
In step S2, the drying is carried out at 20-45 ℃ for 10 minutes.
Example 5
A degradable slow-release invisible eye mask for eliminating asthenopia comprises the following raw material components in 10 ml: 300mg of collagen peptide, 1.2mg of hyaluronic acid, 66 mg mg of vitamin B, 122.2mg of vitamin B, 11mg of dipotassium glycyrrhizinate, 0.22mg of naphazoline hydrochloride, 0.32mg of neostigmine methosulfate, 1.2mg of chlorpheniramine maleate, 150mg of glycerol, 9mg of dexpanthenol, 6mg of menthol, 807 mg of polysorbate, 7mg of borneol, 5mg of edetate disodium, 4mg of mint, 4mg of aminocaproic acid, 3mg of ethanol, 11mg of sodium chloride, 4mg of benzalkonium chloride solution and 5mg of chlorobutanol solution.
The mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
The preparation method of the degradable slow-release invisible eye mask capable of eliminating asthenopia comprises the following steps:
s1, uniformly mixing raw material components to prepare eye mask liquid;
s2, dripping the eye mask liquid into a mold, freezing at a low temperature to solidify and form, demolding, and drying to obtain a dry degradable slow-release invisible eye mask capable of eliminating asthenopia;
and S3, preparing the dried degradable slow-release invisible eye mask capable of eliminating asthenopia.
In step S2, the low-temperature freezing is performed at-4 to 0 ℃ for 5 minutes.
In step S2, the drying is carried out at 20-45 ℃ for 10 minutes.
Test examples
Eye fatigue eliminating effect test
The test contents are as follows: and (3) randomly selecting 50 local consumers wearing the contact lenses for a long time, wearing the degradable slow-release type contact eye mask for eliminating the asthenopia prepared in the embodiment 3 for 30 minutes after wearing the contact lenses for 4 hours, and testing the effect of relieving the asthenopia.
The invention provides a use method of a degradable slow-release invisible eye mask for eliminating asthenopia, which comprises the following steps: immersing the eye mask in the pupil beautifying liquid, placing the eye mask in a refrigerator at 4 ℃ for more than 15 minutes to ensure that the eye mask is taken out after completing water absorption and expansion, and wearing the eye mask on eyes. Wherein, every 10ml of the pupil beautifying liquid comprises the following raw material components: 10mg of purified water, 40mg of hyaluronic acid, 5mg of a 0.01% benzalkonium chloride solution and 5mg of 0.2% chlorobutanol.
| Effect of relieving asthenopia | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 |
| Disappearance of asthenopia | 45 | 46 | 43 | 47 | 46 |
| Eye fatigue reduction | 4 | 2 | 4 | 1 | 3 |
| Invalidation | 1 | 2 | 3 | 2 | 1 |
| High efficiency | 98％ | 96％ | 94％ | 96％ | 98％ |
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; such modifications and substitutions do not depart from the spirit and scope of the present invention, and they should be construed as being included in the following claims and description.
Claims (9)
1. A degradable slow-release invisible eye mask for eliminating asthenopia is characterized in that: the raw material components of the invisible eye mask, calculated by 10ml, comprise: 200-300 mg of collagen peptide, 0.8-1.2mg of hyaluronic acid, 64-6 mg of vitamin B, 121.8-2.2 mg of vitamin B, 9-11mg of dipotassium glycyrrhizinate, 0.18-0.22mg of naphazoline hydrochloride, 0.28-0.32mg of neostigmine methylsulfate, 0.8-1.2mg of chlorphenamine maleate, 80-150mg of glycerol, 7-9mg of dexpanthenol, 4-6mg of menthol, 805-7 mg of polysorbate, 5-7mg of borneol, 3-5mg of edetate disodium, 2-4mg of mint, 2-4mg of aminocaproic acid, 1-3mg of ethanol, 9-11mg of sodium chloride, 2-4mg of benzalkonium chloride solution and 3-5mg of chlorobutanol solution; the mass fraction of the benzalkonium chloride solution is 0.01 percent; the mass fraction of the chlorobutanol solution is 0.2%.
2. The degradable slow-release invisible eye mask capable of eliminating asthenopia according to claim 1, wherein: the raw material components of the invisible eye mask, calculated by 10ml, comprise: 200mg of collagen peptide, 0.8mg of hyaluronic acid, 64 mg mg of vitamin B, 121.8mg of vitamin B, 9mg of dipotassium glycyrrhizinate, 0.18mg of naphazoline hydrochloride, 0.28mg of neostigmine mesylate, 0.8mg of chlorpheniramine maleate, 80mg of glycerol, 7mg of dexpanthenol, 4mg of menthol, 805 mg of polysorbate, 5mg of borneol, 3mg of edetate disodium, 2mg of mint, 2mg of aminocaproic acid, 1mg of ethanol, 9mg of sodium chloride, 2mg of benzalkonium chloride solution and 3mg of chlorobutanol solution.
3. The degradable slow-release invisible eye mask capable of eliminating asthenopia according to claim 1, wherein: the raw material components of the invisible eye mask, calculated by 10ml, comprise: 225mg of collagen peptide, 0.9mg of hyaluronic acid, 0.64.5 mg of vitamin B, 121.9 mg of vitamin B, 9.5mg of dipotassium glycyrrhizinate, 0.19mg of naphazoline hydrochloride, 0.29mg of neostigmine methosulfate, 0.9mg of chlorpheniramine maleate, 97.5mg of glycerol, 7.5mg of dexpanthenol, 4.5mg of menthol, 805.5 mg of polysorbate, 5.5mg of borneol, 3.5mg of disodium edetate, 2.5mg of mint, 2.5mg of aminocaproic acid, 1.5mg of ethanol, 9.5mg of sodium chloride, 2.5mg of benzalkonium chloride solution and 3.5mg of chlorobutanol solution.
4. The degradable slow-release invisible eye mask capable of eliminating asthenopia according to claim 1, wherein: the raw material components of the invisible eye mask, calculated by 10ml, comprise: 250mg of collagen peptide, 1mg of hyaluronic acid, 65 mg of vitamin B, 122 mg of vitamin B, 10mg of dipotassium glycyrrhizinate, 0.20mg of naphazoline hydrochloride, 0.3mg of neostigmine mesylate, 1mg of chlorpheniramine maleate, 115mg of glycerol, 8mg of dexpanthenol, 5mg of menthol, 806 mg of polysorbate, 6mg of borneol, 4mg of edetate disodium, 3mg of mint, 3mg of aminocaproic acid, 2mg of ethanol, 10mg of sodium chloride, 3mg of a benzalkonium chloride solution and 4mg of a chlorobutanol solution.
5. The degradable slow-release invisible eye mask capable of eliminating asthenopia according to claim 1, wherein: the raw material components of the invisible eye mask, calculated by 10ml, comprise: 275mg of collagen peptide, 1.1mg of hyaluronic acid, 0.21mg of naphazoline hydrochloride, 0.31mg of neostigmine methosulfate, 1.1mg of chlorpheniramine maleate, 132.5mg of glycerol, 8.5mg of dexpanthenol, 5.5mg of menthol, 806.5 mg of polysorbate, 6.5mg of borneol, 4.5mg of edetate disodium, 3.5mg of mint, 3.5mg of aminocaproic acid, 2.5mg of ethanol, 10.5mg of sodium chloride, 3.5mg of benzalkonium chloride solution and 4.5mg of chlorobutanol solution.
6. The degradable slow-release invisible eye mask capable of eliminating asthenopia according to claim 1, wherein: the raw material components of the invisible eye mask, calculated by 10ml, comprise: 300mg of collagen peptide, 1.2mg of hyaluronic acid, 66 mg mg of vitamin B, 122.2mg of vitamin B, 11mg of dipotassium glycyrrhizinate, 0.22mg of naphazoline hydrochloride, 0.32mg of neostigmine methosulfate, 1.2mg of chlorpheniramine maleate, 150mg of glycerol, 9mg of dexpanthenol, 6mg of menthol, 807 mg of polysorbate, 7mg of borneol, 5mg of edetate disodium, 4mg of mint, 4mg of aminocaproic acid, 3mg of ethanol, 11mg of sodium chloride, 4mg of benzalkonium chloride solution and 5mg of chlorobutanol solution.
7. The method for preparing the degradable slow-release invisible eye mask for eliminating asthenopia according to any one of claims 1 to 6, which is characterized in that: the preparation method comprises the following steps: s1, uniformly mixing raw material components to prepare eye mask liquid; s2, dripping the eye mask liquid into a mold, freezing at a low temperature to solidify and form, demolding, and drying to obtain a dry degradable slow-release invisible eye mask capable of eliminating asthenopia; and S3, preparing the dried degradable slow-release invisible eye mask capable of eliminating asthenopia.
8. The method for preparing the degradable slow-release invisible eye mask capable of eliminating asthenopia according to claim 7, wherein the degradable slow-release invisible eye mask comprises the following steps: in step S2, the low-temperature freezing is performed at-4 to 0 ℃ for 5 minutes.
9. The method for preparing the degradable slow-release invisible eye mask capable of eliminating asthenopia according to claim 7, wherein the degradable slow-release invisible eye mask comprises the following steps: in step S2, the drying is carried out at 20-45 ℃ for 10 minutes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010903316.7A CN111956791A (en) | 2020-09-01 | 2020-09-01 | Degradable slow-release invisible eye mask capable of eliminating asthenopia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010903316.7A CN111956791A (en) | 2020-09-01 | 2020-09-01 | Degradable slow-release invisible eye mask capable of eliminating asthenopia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111956791A true CN111956791A (en) | 2020-11-20 |
Family
ID=73400246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010903316.7A Pending CN111956791A (en) | 2020-09-01 | 2020-09-01 | Degradable slow-release invisible eye mask capable of eliminating asthenopia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111956791A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115363974A (en) * | 2021-12-21 | 2022-11-22 | 广州栋方生物科技股份有限公司 | Easily-absorbed freeze-dried eye mask composition and preparation method thereof |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455634A (en) * | 2009-01-06 | 2009-06-17 | 河北科技大学 | Composite aspartate, vitamin B6 and dipotassium glycyrrhetate eye drops without bacteria inhibitor and preparation method thereof |
| CN102166203A (en) * | 2011-04-22 | 2011-08-31 | 沈阳药科大学 | Eye pad for alleviating eye fatigue and preparation method thereof |
| CN102342908A (en) * | 2011-10-08 | 2012-02-08 | 西安科威医疗科技有限公司 | Collagen cornea |
| JP2012144509A (en) * | 2011-01-12 | 2012-08-02 | Saga Seiyaku Kk | Ophthalmic solution compounded with many ingredients |
| CN103655373A (en) * | 2013-12-23 | 2014-03-26 | 青岛安信医疗器械有限公司 | Eye mask |
| CN106109331A (en) * | 2016-08-01 | 2016-11-16 | 广州赛莱拉干细胞科技股份有限公司 | A kind of eye mask and preparation method thereof |
| CN107519118A (en) * | 2017-08-31 | 2017-12-29 | 广西小燕蛇业有限公司 | A kind of snake gall eye mask and preparation method thereof |
-
2020
- 2020-09-01 CN CN202010903316.7A patent/CN111956791A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455634A (en) * | 2009-01-06 | 2009-06-17 | 河北科技大学 | Composite aspartate, vitamin B6 and dipotassium glycyrrhetate eye drops without bacteria inhibitor and preparation method thereof |
| JP2012144509A (en) * | 2011-01-12 | 2012-08-02 | Saga Seiyaku Kk | Ophthalmic solution compounded with many ingredients |
| CN102166203A (en) * | 2011-04-22 | 2011-08-31 | 沈阳药科大学 | Eye pad for alleviating eye fatigue and preparation method thereof |
| CN102342908A (en) * | 2011-10-08 | 2012-02-08 | 西安科威医疗科技有限公司 | Collagen cornea |
| CN103655373A (en) * | 2013-12-23 | 2014-03-26 | 青岛安信医疗器械有限公司 | Eye mask |
| CN106109331A (en) * | 2016-08-01 | 2016-11-16 | 广州赛莱拉干细胞科技股份有限公司 | A kind of eye mask and preparation method thereof |
| CN107519118A (en) * | 2017-08-31 | 2017-12-29 | 广西小燕蛇业有限公司 | A kind of snake gall eye mask and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 张美云等: "胶原蛋白/羧甲基纤维素(CMC)膜的制备及其力学性能研究", 中国皮革, vol. 35, no. 13, 8 July 2006 (2006-07-08), pages 9 - 12 * |
| 张美云等: "胶原蛋白/羧甲基纤维素(CMC)膜的制备及其力学性能研究", 中国皮革, vol. 35, no. 13, pages 9 - 12 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115363974A (en) * | 2021-12-21 | 2022-11-22 | 广州栋方生物科技股份有限公司 | Easily-absorbed freeze-dried eye mask composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1165731B1 (en) | A viscosity enhanced ophthalmic solution, having a detergent action on contact lenses | |
| Papa et al. | Comparison of hypotonic and isotonic solutions containing sodium hyaluronate on the symptomatic treatment of dry eye patients | |
| Burgalassi et al. | Development of a simple dry eye model in the albino rabbit and evaluation of some tear substitutes | |
| US6273092B1 (en) | Methods for treating various eye disorders | |
| Ikeda et al. | Alkali burns of the eye: effect of immediate copious irrigation with tap water on their severity | |
| CN102164592A (en) | Use of enhancers, possibly associated to riboflavin, as well as corresponding ophthalmic compositions for corneal cross-linking in the treatment of the keratoconus or of other corneal ectasic disorders | |
| CN103068364B (en) | Bimatoprost without preservative and timolol solution | |
| JP2006282586A (en) | Composition for ophthalmology | |
| JP2009515921A (en) | Pharmaceutical composition free of dexpantenol, calcium ions and phosphate, and the use of calcium chelators and ophthalmically compatible viscosity modifiers | |
| CN111956791A (en) | Degradable slow-release invisible eye mask capable of eliminating asthenopia and preparation method thereof | |
| Labetoulle et al. | Safety and efficacy of a hydroxypropyl guar/polyethylene glycol/propylene glycol-based lubricant eye-drop in patients with dry eye | |
| EP1244449A1 (en) | Use of ketotifen as ophthalmic agent | |
| KR20140107383A (en) | Efficient lipid delivery to human tear film using a salt-sensitive emulsion system | |
| US20120269845A2 (en) | Opthalmic composition containing xanthan gum and amino acid | |
| JPWO2018074421A1 (en) | Ophthalmic agent and ophthalmic drug | |
| CN106492231B (en) | A kind of lidocaine hydrochloride cavity lubrication is dispelled infusion | |
| CN105983004A (en) | Composition capable of alleviating asthenopia and preparation method | |
| WO2020140365A1 (en) | Moisturizing and lubricating composition containing xanthan gum and use thereof | |
| JP2012031184A (en) | Ophthalmic composition | |
| Ozkan et al. | Lubricant effects on low Dk and silicone hydrogel lens comfort | |
| CN114288318A (en) | Eye lotion containing schizophyllan and preparation method thereof | |
| van den Bergh et al. | On the selectivity of photodynamic therapy of choroidal neovascularization associated with age-related macular degeneration | |
| JP2005239622A (en) | Therapeutic agent for corneal disorder | |
| Ghanem et al. | Photorefractive keratectomy with mitomycin C in meesmann's epithelial corneal dystrophy | |
| EP3127543B1 (en) | Ophthalmic formulations comprising oligosaccharides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |